Samsung Biologics, Kanaph Therapeutics partner on retinal disease therapy

By The Science Advisory Board staff writers

September 24, 2020 -- Samsung Biologics and Kanaph Therapeutics are partnering on the development of KNP-301, a bispecific Fc fusion protein to treat retinal diseases.

KNP-301 is designed to treat complement-mediated and angiogenesis-driven retinal diseases by suppressing both complement component 3 (C3b) and vascular endothelial growth factor (VEGF) as a bispecific approach. The therapy is the first biologics program out of Kanaph Therapeutics that is preparing for global clinical trials.

Under the agreement, Samsung Biologics will provide full contract development organization services including cell line development, process development, nonclinical and clinical material manufacturing, and investigational new drug submission.

Samsung Biologics, AstraZeneca ink manufacturing deal
Samsung Biologics and AstraZeneca have signed a $330.8 million long-term supply agreement.
PharmAbcine, Samsung Biologics expand partnership
PharmAbcine and Samsung Biologics have entered into a new strategic partnership for the development and manufacturing of PMC-403, a next-generation antibody...
Samsung Biologics adds new manufacturing plant
Samsung Biologics announced that it plans to break ground on a fourth plant in South Korea this year as part of a strategy to scale up development and...
Samsung Biologics, Vir partner on SARS-CoV-2 program
Samsung Biologics announced it will manufacture Vir Biotechnology's SARS-CoV-2 monoclonal antibody program for a potential COVID-19 treatment.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter